drugset
drugset / Trial / NCT05012670

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

NCT05012670 ↗

Phase 1 Completed 6 enrolled Kazia Therapeutics Limited Quotient Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

Single-centre, open-label, non-randomised study to assess the mass balance recovery, PK, metabolite profile, and metabolite identification of a single oral dose of 14C labelled paxalisib (\[14C\] Paxalisib) in healthy male subjects.

Timeline

Start
2021-08-18
Primary completion
2023-03-30
Completion
2024-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Paxalisib Small molecule 15 mg Oral

Indications

No indication recorded.